The FDA has granted Priority Review to Boehringer Ingelheim's new drug application for its non-small cell lung cancer therapy ...

The U.S. Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib (BI 1810631) for the treatment of adult patients with ...

Laboratory Illustrative image Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally ...

Dr. Terence Kelly named interim CEO and Prof. Damian O'Connell named Chair of the Scientific Advisory Board, joins Board of Directors - Appointment ...

Five regions in the U.S. have been selected to implement a new preventive health initiative to improve care for people with a cluster of chronic conditions known as cardiovascular-kidney-metabolic ...

American Heart Association initiative aims to improve care for people in Atlanta; Baton Rouge, La.; Washington, D.C.; Maryland; San Diego and Ohio who have a cluster of conditions called cardiovascula ...

A new generative AI tool developed by Mass General Brigham researchers, called RECTIFIER, was more efficient at screening and enrolling patients for a heart failure clinical trial than manual ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses ...

Researchers from Cologne, Bochum, Padova and Angers have discovered a novel connection between mitochondrial function, ...

Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...